vocimagene amiretrorepvec
Gene therapyexperimental
Vocimagene amiretrorepvec/flucytosine is an experimental combination drug involving a gene therapy agent and a prodrug. It is a candidate drug to treat brain cancers. — Wikipedia
Clinical trial activity
11 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Jun 1, 2010 (NCT01156584)
Timeline
Indications
Studied for
- Astrocytoma · Phase 2/Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Colorectal Neoplasms · Phase 1
- Glioblastoma · Phase 2/Phase 3
- Glioma · Phase 2
- Head and Neck Neoplasms · Phase 1
- Lymphoma · Phase 1
- Melanoma · Phase 1
- Methylation · Phase 1
- Neoplasms · Phase 1
- Oligodendroglioma · Phase 2/Phase 3
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Sarcoma · Phase 1
- Triple Negative Breast Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
Mechanism of action
- Cytidine deaminaseSupplementation
CDA supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVocimagene amiretrorepvec/flucytosine ↗
- ChEMBLCHEMBL2108627 ↗
- WikipediaToca 511 and Toca FC ↗
Also known as
- toca 511
- toca-511
- vocimagene amiretrorepvec
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06504381 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2024 | California Institute for Regenerative Medicine (CIRM), University of California, San Francisco |
| NCT06264388 | Phase 2 | May 1, 2024 | Denovo BioPharma, National Cancer Institute (NCI), University of Miami |
| NCT04105374 | Phase 2/Phase 3 (Phase 3) | Jan 31, 2020 | National Cancer Institute (NCI), NRG Oncology |
| NCT04089163 | Phase 1 | Dec 31, 2019 | Tocagen Inc. |
| NCT02576665 | Phase 1 | Jul 1, 2016 | Tocagen Inc., University of Miami |
| NCT02598011 | Phase 1 | Mar 1, 2016 | Tocagen Inc. |
| NCT02414165 | Phase 2/Phase 3 (Phase 3) | Nov 1, 2015 | Tocagen Inc., University of California, Los Angeles |
| NCT01985256 | Phase 1 | Oct 1, 2013 | Tocagen Inc. |
| NCT01470794 | Phase 1 | Jan 1, 2012 | Tocagen Inc. |
| NCT04327011 | Phase 1 | Feb 28, 2011 | The Cleveland Clinic, Tocagen Inc. |
| NCT01156584 | Phase 1 | Jun 1, 2010 | Tocagen Inc. |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tocagen Inc. | For profit | 8 | 8 | 2 | 2010 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2020 |
| University of Miami | Academic/Hospital | 2 | 1 | 2 | 2016 |
| California Institute for Regenerative Medicine (CIRM) | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Denovo BioPharma | For profit | 1 | 0 | 1 | 2024 |
| NRG Oncology | Academic/Hospital | 1 | 1 | 1 | 2020 |
| The Cleveland Clinic | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2024 |
9 organizations
Page 1 / 1